Prostate Cancer—Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/prost.html.

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, et al. NCCN Guidelines version 1.2023 Prostate Cancer. J Natl Compr Canc Netw. 2022;20(12):1288–98.

PubMed  Google Scholar 

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S, et al. Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 2018;9(97):36966–74.

Article  PubMed  PubMed Central  Google Scholar 

Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, Álvarez-Gómez RM, Montiel-Manríquez R, Castro-Hernández C, et al. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. Prostate Cancer Prostatic Dis. 2022;25(3):431–43.

Article  PubMed  PubMed Central  Google Scholar 

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017;81:228–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, et al. A Phase II Study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian Cancer Trials Group Study IND205. Clin Genitourin Cancer. 2019;17(3):201-208.e1.

Article  PubMed  Google Scholar 

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer. 2017;76:36–44.

Article  CAS  PubMed  Google Scholar 

Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science. 2019;366(6466):714–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.

Article  PubMed  Google Scholar 

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS One. 2022;17(3):e0264138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):1–14.

Article  Google Scholar 

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, et al. A novel next-generation sequencing approach to detecting microsatellite instability and Pan-Tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn. 2019;21(6):1053–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Connelly CF, Carrot-Zhang J, Stephens PJ, Frampton GM. Somatic genome alterations in cancer as compared to inferred patient ancestry. Cancer Res. 2018;78(13_Supplement):1227.

Article  Google Scholar 

Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, et al. Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response. JCO Precis Oncol. 2023:7:e2300093.

Article  PubMed  Google Scholar 

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–102.

Article  PubMed  Google Scholar 

Cham J, Venkateswaran AR, Bhangoo M. Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: a review article. Clin Genitourin Cancer. 2021;19(6):563.e1-563.e7.

Article  PubMed  Google Scholar 

Tortorella E, Giantulli S, Sciarra A, Silvestri I. AR and PI3K/AKT in prostate cancer: a tale of two interconnected pathways. Int J Mol Sci. 2023;24(3):2046.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, et al. Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer. Eur Urol. 2020;78(6):834–44.

Article  CAS  PubMed  Google Scholar 

Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):1–47.

Article  Google Scholar 

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, et al. Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth. Cancer Discov. 2018;8(6):764–79.

Article  CAS  PubMed  Google Scholar 

Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, et al. A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors. Clin Cancer Res. 2022;28(11):2257–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarker D, Dawson NA, Aparicio AM, Dorff TB, Pantuck AJ, Vaishampayan UN, et al. A phase I, open-label, dose-finding study of GSK2636771, a PI3Kβ inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2021;27(19):5248–57.

Article  CAS  PubMed  Google Scholar 

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, et al. Phosphatidylinositol 3-kinase α-selective inhibition with Alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36(13):1291.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398(10295):131–42.

Article  CAS  PubMed  Google Scholar 

Bou-Dargham MJ, Sha L, Sang QXA, Sang QXA, Zhang J. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer. 2020;20(1):572.

Article  PubMed  PubMed Central  Google Scholar 

Graff JN, Liang LW, Kim J, Stenzl A. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(23):3017–26.